Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference10 articles.
1. Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med. 2017;15:134.
2. Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival. An analysis of 5 years of US Food and Drug Administration approvals. JAMA. 2015;175:1992–4.
3. Davis C. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017;359:j4530.
4. Kloecker DE, Davies MJ, Khunti K, Zaccardi F. Uses and limitations of the restricted mean survival time: illustrative examples from cardiovascular outcomes and mortality trials in type 2 diabetes. Ann Intern Med. 2020. https://doi.org/10.7326/M19-3286. Online ahead of print. PMID: 32203984.
5. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–64.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献